Shop Antibodies
Best Seller

De Novo Human Antibody Discovery & Maturation

$18,950.00

Item Cat No.: BCHULI

Antibody: Monoclonal Antibody

Concentration: 1 mg/ml purified IgG

Application: In Vitro and In Vivo

Reactivity: Human

BiCell Scientific’s de novo human antibody discovery & maturation service utilizes a unique and proprietary yeast display platform to experimentally select human IgG molecules from a synthetic human antibody library.

Synthetic libraries of human antibodies have previously been used in phage display to identify potential lead molecules for therapeutic applications. Phage display, being expressed in bacteria, has intrinsic limitations largely related to prokaryotic protein expression machinery misfolding human antibody or its Fv domain. Yeast display, being processed in the endoplasmic reticulum of eukaryotic cells, can present human antibody protein in its bona fide structural conformation.

BiCell Scientific’s human synthetic antibody library is constructed from a consensus framework derived from both human genome (germline) and single B cell RNA-seq database. The constant framework is combined with designed variations in the complementarity-determined loops (CDRs) that comprise the highly variable antigen-binding interface. Randomization of residue composition in the CDRs is achieved by using a mixed pool of timer phosphoramidites to match target codon frequency. The resulting synthetic antibody library contains at least 1 × 108 unique antibody clones that are able to be expressed and displayed on the yeast cell surface. By using MACS and FACS enrichment techniques, BiCell Scientific’s de novo human antibody discovery & maturation service can guarantee the selection of human antibodies with binding affinity of EC50 value at 10 nM or less.

  • Construct yeast display library vector pYSD series, expressing the scFv form of fused Fv domains from heavy chain and light chain.
  • Transform pYSD libraries into EBY100 YSD yeast strain.
  • Harvest yeast cells with induced expression of scFv. Perform antigen based binding enrichment with MACS and FACS.
  • Recover sorted yeast cells and plate them to form single colonies.
  • Clone the scFv gene sequences from recovered yeast cells into lentiviral expression vector.
  • Transfection of HEK293T cells with lentiviral expression vectors as well as vectors expressing gagpol, rev and vsvg
  • Harvesting and purification of lentivirus from cell culture medium
  • Transducing naive Sp2/0-Ag14 hybridoma cells with lentivirus encoding human IgG
  • Clonal selection and stable cell line establishment in 96-well plate
  • Validation of human IgG antibody expression in 96-well plate against antigen and selection of the highest expressing clone
  • Affinity chromatography purification with protein A column

Customers will receive the following deliverables at the end of each project:

  • Fully sequenced Fv domains of heavy chain and light chain of the selected human antibody
  • One stable Sp2/0-Ag14 hybridoma cell line expressing human monoclonal antibody with the highest yield
  • 1 mg of affinity purified human monoclonal antibody

(Customers select the clone of their interest. BiCell Scientific Inc will bank the remaining clones. Additional clones are offered at $950 each).


For Research Use Only. Not for use in clinical diagnostics or therapeutics.

  • Initial screening of yeast display library against antigen protein – 3-4 weeks
  • One round of MACS enrichment and maturation  – 2-3 weeks
  • One round of FACS enrichment and maturation – 2-3 weeks
  • Cloning and sequencing of affinity selected scFv genes from yeast – 2-3 weeks
  • Assembling human IgG in lentiviral expression system – 2-3 weeks
  • Naive Sp2/0-Ag14 hybridoma cell transduction – 1-2 weeks
  • Clonal selection and stable cell line establishment – 3-4 weeks
  • Human antibody expression validation – 2-3 weeks
  • Cell culture expansion and affinity purification – 2-3 weeks

Reviews

There are no reviews yet.

Be the first to review “De Novo Human Antibody Discovery & Maturation”

"I am really impressed with your approach. We tried multiple times previously to create monoclonal and polyclonal antibodies to claudin-2 and MLCK1. We have had limited success generating polyclonals and no success generating monoclonals. You have generated outstanding monoclonals to both. I look forward to continuing to work with you."

Jerrold R. Turner, M.D., Ph.D.

Brigham and Women’s Hospital | Harvard Medical School

"The polyclonal antibody you generated for KIAA0408 is stunning! KIAA0408 is a novel cilium molecule that has never been studied. So, clearly there will be a lot of demand for it as we have discovered a very interesting finding and the story will be published in a high impact journal. I am strongly inclined to generate monoclonal antibody for this protein too and we should think about patenting it."

Univ.-Prof. Jay Gopalakrishnan PhD

Heinrich-Heine-Universität | Universitätsklinikum Düsseldorf

"Your ARL13B antibody works beautifully!!! We’re so happy to have a cilia-specific antibody made in rat! I can send you high resolution images to be posted on your website."

Julie Craft Van De Weghe, PhD

School of Medicine | University of Washington

"The assay is a homophilic interaction mediated cell adhesion on purified protein (in this case, immobilized purified Pcdhga9 to Pcdhga9 expressed on cell surface). Compared to control, cell adhesion is reduced in the presence of Pcdhga9 monoclonal antibody supernatants!"

Divyesh Joshi, PhD

School of Medicine | Yale University

"The rabbit hybridoma supernatants of anti-APOBEC3 project are tested positive by ELISA, and we are very happy about it! We previously tried a company, Abclone. Their Project "A" has immune response that is <10,000 titer in antiserum, which would explain why there is no positive mAb after fusion. Their project "B" didn't have any immune response in rabbit."

Harshita B Gupta, PhD.

School of Medicine | UT Health San Antonio

"We have tested anti mouse T cell antiserum samples from both rabbits you sent to us.

They worked very well! Thank you!"

Victoria Gorbacheva, PhD.

School of Medicine | Cleveland Clinic

Contact us for questions or custom requests!